Janssen Research & Development, Llc

This phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…

This phase 2 trial tested a combination of two drugs—TAR-200 (placed directly into the bladder) and cetrelimab (an immunotherapy given by IV)—in 163 people with muscle-invasive bladder cancer who were scheduled for bladder removal surgery and could not or would not take standard …

This completed Phase 3 trial tested the drug guselkumab (Tremfya) in 211 people with skin of color who have moderate-to-severe plaque psoriasis or scalp psoriasis. Participants received either guselkumab or a placebo injection. The study measured how well the drug cleared skin le…

This completed Phase 1/2 trial tested a combination of two drugs, amivantamab and docetaxel, in 12 people with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumors. The study focused on patients whose cance…

This phase 3 study tested whether the drug daratumumab, given as a shot under the skin, could delay or prevent smoldering multiple myeloma from turning into active multiple myeloma. 390 people with high-risk smoldering myeloma were randomly assigned to receive daratumumab or to b…

This large phase 3 study tested whether milvexian, an oral blood thinner, can reduce the risk of major cardiovascular events like heart attack, stroke, or death in people who recently had an acute coronary syndrome (heart attack or unstable angina). Over 14,000 participants took …

This Phase 3 study tested guselkumab, a drug given by injection, in 741 adults with active psoriatic arthritis. The goal was to see if it reduces joint pain and swelling. Participants received either guselkumab or a placebo. The main measure was a 20% improvement in arthritis sym…

This study tested a new oral medication, JNJ-77242113, for long-term control of moderate-to-severe plaque psoriasis. 227 adults who completed a previous 16-week study continued treatment for up to 36 more weeks. The goal was to see how well the drug kept skin clear over time.

This phase 3 study tested whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, dexamethasone) helps people with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. The main goal was to see if more patients achieve a …

This study tested a drug called ustekinumab in 112 children with moderate-to-severe ulcerative colitis, a condition causing inflammation in the colon. The goal was to see if the drug could reduce symptoms like diarrhea and bleeding and help the colon heal. Children first received…

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This study tested an oral tablet called JNJ-77242113 in 90 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive the drug or a placebo for 16 weeks. The main goal was to see if the drug could improve psoriasis symptoms by at least 75% com…

This completed phase 3 trial tested the drug guselkumab against a placebo in 338 adults with moderate plaque psoriasis covering only 2-15% of their body but including special sites like the scalp, face, or genitals. The goal was to see if guselkumab could clear or nearly clear ps…

This study tested whether adding apalutamide to standard hormone therapy after prostate removal surgery can keep prostate cancer from coming back in high-risk patients. 108 men who had surgery for non-spread prostate cancer took the drug combo for up to 2 years. Researchers check…

This phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete response…

This early-phase study tested a new treatment called JNJ-75229414, which uses a patient's own immune cells (T cells) engineered to attack prostate cancer cells. The study involved 15 men with metastatic castration-resistant prostate cancer that had already been treated with other…

This completed Phase 2b trial tested an oral tablet called JNJ-77242113 against placebo in 252 adults with moderate-to-severe ulcerative colitis. The goal was to see if the drug could reduce symptoms and inflammation better than a dummy pill. Researchers measured clinical respons…

This study tested whether combining two drugs (guselkumab and golimumab) works better than one drug alone for people with active psoriatic arthritis who didn't get enough relief from previous TNF-alpha blockers. 91 adults took part. The goal was to see if the combo could help mor…

This study tested an experimental drug called M281 (nipocalimab) in 25 pregnant women at high risk for early-onset severe hemolytic disease of the fetus and newborn (HDFN), a condition where the mother's immune system attacks the baby's red blood cells. The goal was to see if the…

This Phase 3 trial tests a gene therapy called botaretigene sparoparvovec for X-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. The study involves 105 participants who receive the therapy via injection under the retina. The main goal is to se…

This study tested a new drug called daratumumab, given together with two standard treatments (lenalidomide and dexamethasone), in 45 people whose multiple myeloma had returned or stopped responding to prior therapy. The main goal was to check safety and see how many patients resp…

This study tested a gene therapy called JNJ-81201887 in 305 people with geographic atrophy, a late stage of dry age-related macular degeneration that causes blind spots. The treatment is injected into the eye and aims to slow the growth of damaged areas. Researchers measured chan…

This phase 2 trial tested a daily pill called erdafitinib against standard chemotherapy for people with a high-risk bladder cancer that returned after BCG treatment. The study enrolled 107 participants whose tumors have specific FGFR gene changes. The goal was to see if erdafitin…

This early-phase study tested a new drug called JNJ-70218902 in 82 people with advanced solid tumors, including prostate cancer. The drug works by redirecting the body's immune T cells to attack cancer cells. The main goals were to find a safe dose and check for side effects, not…

This study tested an experimental drug called JNJ-77242113 in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could clear at least 75% of skin symptoms after 16 weeks compared to a placebo. Participants had psoriasis for at least 6 mont…

This study followed 42 people who received a gene therapy for X-linked retinitis pigmentosa, an inherited eye disease that causes blindness. The goal was to check the treatment's safety over up to 5 years. Researchers also looked at whether patients' vision and ability to move ar…

This study tested a drug called niraparib in 289 men with advanced prostate cancer that no longer responds to hormone therapy and has specific DNA repair issues. The goal was to see if the drug could shrink tumors or slow the disease. Results may help identify which patients coul…

This early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…

This Phase 2 trial tested nipocalimab, an intravenous drug, in 228 adults with active systemic lupus erythematosus (SLE). Participants received either nipocalimab or a placebo, alongside standard treatments. The main goal was to see if nipocalimab could reduce lupus disease activ…

This study tested whether adding daratumumab to standard chemotherapy (CyBorD) helps people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 416 adults took part. The goal was to see if the combination leads to better blood res…

This study tested whether ustekinumab, a drug that blocks inflammation, can help children aged 2 to 17 with moderate-to-severe Crohn's disease. 101 participants first received the drug through an IV, then some continued with injections while others got a placebo. The goal was to …

This study tested an intravenous drug called golimumab in 130 children with active juvenile idiopathic arthritis that did not improve with methotrexate. The main goal was to measure how the drug moves through the body over time. The study was completed and provides information on…

This study tested an experimental drug called nipocalimab in 163 adults with primary Sjogren's syndrome, an autoimmune disease causing dryness and fatigue. Participants received either the drug or a placebo for 24 weeks. The goal was to see if nipocalimab could reduce overall dis…

This Phase 3 trial tested golimumab, an anti-inflammatory biologic, given as an IV infusion to 208 people with active ankylosing spondylitis. Participants received either golimumab or a placebo. The main goal was to see if more people on golimumab had at least a 20% improvement i…

This phase 3 study compared a three-drug combination (daratumumab, lenalidomide, and dexamethasone) against the standard two-drug regimen (lenalidomide and dexamethasone) in 737 people with newly diagnosed multiple myeloma who could not undergo high-dose chemotherapy and stem cel…

This study tested whether adding nipocalimab to the standard drug certolizumab works better than certolizumab alone for people with active rheumatoid arthritis. It involved 103 adults who still had moderate to severe symptoms despite trying other advanced treatments. The main goa…

This early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safe…

This study tested a combination of ibrutinib and rituximab against other standard drug pairs in 36 people with mantle cell lymphoma that had returned or stopped responding to treatment. The main goal was to check safety and side effects, and to keep giving the treatment to those …

This early-stage study tested a new drug called JNJ-74856665 in 153 people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). The main goals were to find safe doses and check for side effects when given alone or with oth…

This study tested the drug ustekinumab (STELARA) in 182 Chinese adults with moderate-to-severe Crohn's disease. The goal was to see if the drug could reduce symptoms and heal the gut lining over 52 weeks. Participants received the drug by IV and later by injection, and researcher…

This completed study looked for specific molecules in the blood (called microRNAs) that could help detect pulmonary hypertension (PH) early. Researchers analyzed blood samples from 907 participants who had or were scheduled for a right heart catheterization, the standard diagnost…

This study tested an experimental vaccine (ExPEC10V) in 836 healthy adults aged 60 to 85 to see if it can prevent infections caused by a harmful type of E. coli. Participants received one of three vaccine doses or a placebo, and researchers monitored side effects and immune respo…

This large Phase 3 trial tested a vaccine called ExPEC9V in nearly 18,000 adults aged 60 and older who had a urinary tract infection in the past two years. The goal was to see if the vaccine could prevent invasive E. coli disease, a serious infection that can spread to the blood …

This study tested whether a new vaccine against certain E. coli bacteria (ExPEC9V) can be given at the same time as a high-dose flu shot in adults aged 65 and older. The goal was to see if the immune response to both vaccines remains strong when given together. About 959 particip…

This study tested whether adding seltorexant, a sleep-related drug, to standard antidepressants helps improve depression symptoms in adults with major depression and insomnia. About 588 participants who hadn't responded well enough to their current antidepressant took either selt…

This study tested whether adding aticaprant to a standard antidepressant helps adults with major depression who still feel little pleasure or interest (anhedonia). About 444 people took either aticaprant or a placebo pill for 6 weeks. The main goal was to see if depressive sympto…

This study tested a drug called aticaprant in 513 adults with major depression who still had symptoms—especially loss of interest or pleasure (anhedonia)—even after taking standard antidepressants. Participants took either aticaprant or a placebo pill alongside their usual antide…

This early-stage study tested a long-acting injectable form of the HIV drug rilpivirine, alone or with another drug called cabotegravir, in 126 healthy adults. The goal was to see how the body processes the drugs and whether they are safe. This trial does not test treatment or pr…

This study looked at 545 people with major depressive disorder who also have anhedonia (loss of interest or pleasure) and whose current antidepressants weren't working well enough. Researchers tracked their symptoms, treatments, and outcomes to better understand the disease and h…

This study followed 17 pregnant women and their babies who were at high risk for early onset severe hemolytic disease of the fetus and newborn (EOS-HDFN). The goal was to see how the condition is currently managed and what outcomes occur. No new drugs were tested; instead, resear…